Mesoblast Limited
MESO
$16.14
-$0.25-1.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 390.73% | 390.73% | 1,526.81% | 1,526.81% | 458.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 390.73% | 390.73% | 1,526.81% | 1,526.81% | 458.55% |
| Cost of Revenue | -337.30% | -337.30% | 957.35% | 957.35% | 130.08% |
| Gross Profit | 6,432.91% | 6,432.91% | -25.66% | -25.66% | -96.58% |
| SG&A Expenses | 35.25% | 35.25% | 58.46% | 58.46% | 57.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 645.45% | 645.45% | -6,253.49% | -6,253.49% | 34.87% |
| Total Operating Expenses | 62.54% | 62.54% | 244.26% | 244.26% | 65.78% |
| Operating Income | 45.99% | 45.99% | -41.71% | -41.71% | -34.50% |
| Income Before Tax | 68.26% | 68.26% | 16.77% | 16.77% | 2.55% |
| Income Tax Expenses | 42.37% | 42.37% | 109.91% | 109.91% | 232.58% |
| Earnings from Continuing Operations | 68.02% | 68.02% | 16.21% | 16.21% | 2.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.02% | 68.02% | 16.21% | 16.21% | 2.18% |
| EBIT | 45.99% | 45.99% | -41.71% | -41.71% | -34.50% |
| EBITDA | 49.23% | 49.23% | -32.56% | -32.56% | -27.94% |
| EPS Basic | 68.54% | 68.54% | 26.19% | 26.19% | 15.48% |
| Normalized Basic EPS | 50.47% | 50.47% | 3.36% | 3.36% | 19.55% |
| EPS Diluted | 68.54% | 68.54% | 25.71% | 25.71% | 15.48% |
| Normalized Diluted EPS | 50.47% | 50.47% | 3.36% | 3.36% | 19.55% |
| Average Basic Shares Outstanding | 1.92% | 1.92% | 13.11% | 13.11% | 15.96% |
| Average Diluted Shares Outstanding | 1.92% | 1.92% | 13.11% | 13.11% | 15.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |